Odonate Therapeutics, Inc.
CIK 0001717452
Revenue (TTM)
—
Q3 Oct 2021
Net Income (TTM)
−$100.26M
−13.0% YoY
Q3 Oct 2021
EPS Diluted (TTM)
—
Q3 Oct 2021
Gross Margin
—
Q3 Oct 2021
Operating Margin
—
Q3 Oct 2021
Net Margin
—
Q3 Oct 2021
Free Cash Flow (TTM)
−$92.4M
Q3 Oct 2021
Cash
$95.74M
Q3 Oct 2021
Total Debt
—
Q3 Oct 2021
Shares Outstanding
38.49M sh
Q3 Oct 2021
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.